Serum neopterin and ischemia modified albumin levels are associated with the disease activity of adult immunoglobulin A vasculitis (Henoch-Schönlein purpura).
IgA vasculitis
disease activity
ischemia modified albumin
neopterin
relapse
Journal
International journal of rheumatic diseases
ISSN: 1756-185X
Titre abrégé: Int J Rheum Dis
Pays: England
ID NLM: 101474930
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
14
01
2019
revised:
23
05
2019
accepted:
05
07
2019
pubmed:
15
8
2019
medline:
9
4
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
The aims of the study are to investigate serum neopterin and ischemia modified albumin (IMA) levels in patients with immunoglobulin A vasculitis (IgAV) and evaluate the association of these markers with disease activity and relapse. Thirty-four consecutive adult patients (24 male and 10 female) admitted to the rheumatology clinic and met the IgAV American College of Rheumatology (ACR) criteria were enrolled in this cross-sectional study. Demographic and clinical features of IgAV and a control group were recorded into a predefined protocol. Disease activity was categorized as "remission" or "active" according to Birmingham Vasculitis Activity Score (BVAS). BVAS ≥ 1 was accepted as "active". Serum neopterin levels, high-sensitivity C-reactive protein (hsCRP) and IMA were evaluated according to BVAS and compared to the healthy control group. Serum median (interquartile range) neopterin, IMA levels and hsCRP were higher in the study group than in control group (2.01 [12.5] ng/mL vs 1.77 [1.37] ng/mL, 0.67 [0.2] ng/mL vs. 0.43 [0.17] ng/mL, 5.6 [17.1] mg/L vs. 1.55 [1.6] mg/L, P = .095, P < .001 and P = .002, respectively). When evaluated according to BVAS, IMA and hsCRP levels were significantly higher in the group with active disease (0.77 [0.12] vs 0.61 [0.13] and 14.85 [4.6], P = .009 and P = .03, respectively). Serum neopterin levels were significantly higher in the active group compared to BVAS (18.95 [32.36] vs 1.63 [1.48], P < .001). Oxidative stress is important in IgAV pathogenesis. Roles of hsCRP, neopterin and IMA as potential markers of diagnosis and disease activity seem to be worth studying in future studies with larger study groups.
Identifiants
pubmed: 31411385
doi: 10.1111/1756-185X.13673
doi:
Substances chimiques
Biomarkers
0
Immunoglobulin A
0
ischemia-modified albumin
0
Neopterin
670-65-5
C-Reactive Protein
9007-41-4
Serum Albumin, Human
ZIF514RVZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1920-1925Informations de copyright
© 2019 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons Australia, Ltd.
Références
Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1-11.
Pillebout E, Thervet E, Hill G, et al. Henoch-Schönlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13:1271-1278.
Makay B, Gücenmez ÖA, Duman M, Ünsal E. The relationship of neutrophil-to-lymphocyte ratio with gastrointestinal bleeding in Henoch-Schonlein purpura. Rheumatol Int. 2014;34:1323-1327.
Johnson EF, Lehman JS, Wetter DA, Lohse CM, Tollefson MM. Henoch-Schonlein purpura and systemic disease in children: retrospective study of clinical findings, histopathology and direct immunofluorescence in 34 paediatric patients. Br J Dermatol. 2015;172:1358-1363.
Nagamori T, Oka H, Koyano S, et al. Construction of a scoring system for predicting the risk of severe gastrointestinal involvement in Henoch-Schönlein Purpura. Springerplus. 2014;2(3):171.
Chuang S-C, Boeing H, Vollset SE, et al. (2016) Cellular immune activity biomarker neopterin is associated hyperlipidemia: results from a large population-based study. ImmunAgeing. 2016;25(13):5.
El-Lebedy D, Hussein J, Ashmawy I, Mohammed AM. Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients. Clin Rheumatol. 2017;36:1975-1979.
Eisenhut M. Neopterin in diagnosis and monitoring of infectious diseases. J Biomarkers. 2013;2013:1-10.
Karaca A, Omma T, Dura Deveci C, et al. Neopterin and hsCRP are not correlated in gestational diabetes mellitus. Gynecol Endocrinol. 2016;32:977-981.
Zeng X, Zhang G, Yang B, et al. Neopterin as a predictor of functional outcome and mortality in Chinese patients with acute ischemic stroke. Mol Neurobiol. 2016;53:3939-3947.
Lewicka E, Dudzińska-Gehrmann J, Dąbrowska-Kugacka A, et al. Neopterin and interleukin-6 as predictors of recurrent atrial fibrillation. Anatol J Cardiol. 2016;16:563-571.
Roy D, Quiles J, Aldama G, et al. Ischemia Modified Albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal ornon-diagnostic 12-lead electrocardiograms and negative cardiac troponin T. Int J Cardiol. 2004;97:297-301.
Jena I, Nayak SR, Behera S, et al. Evaluation of ischemia-modified albumin, oxidative stress, and antioxidant status in acute ischemic stroke patients. J Nat Sci Biol Med. 2017;8:110-113.
Menon B, Ramalingam K, Krishna V. Study of ischemia modified albumin as a biomarker in acute ischaemic stroke. Ann Neurosci. 2018;25:187-190.
Guntas G, Sahin A, Duran S, et al. Evaluation of ischemia-modified albumin in patients with inflammatory bowel disease. Clin Lab. 2017;63:341-347.
Bahinipati J, Mohapatra PC. Ischemia modified albumin as a marker of oxidative stress in normal pregnancy. J Clin Diagn Res. 2016;10:15-17.
Kılıç MÖ, Güldoğan CE, Balamir İ, Tez M. Ischemia-modified albumin as a predictor of the severity of acute appendicitis. Am J Emerg Med. 2017;35:92-95.
Kılıç S, Işık S, Hiz MM, et al. The ischemia modified albumin and mean platelet volume levels in patients with Behçet's disease. Postepy Dermatol Alergol. 2016;33:345-348.
Leitemperguer MR, Tatsch E, Kober H, De Carvalho JA, Moresco RN, Da Silva JE. Assessment of ischemia-modified albumin levels in patients with rheumatoid arthritis. Clin Lab. 2014;60:1065-1070.
Luqmani RA, Bacon PA, Moots RJ, et al. Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM. 1994;87:671-678.
Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68:1827-1832.
Suppiah R, Mukhtyar C, Flossmann O, et al. A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford). 2011;50:899-905.
Merkel PA, Aydin SZ, Boers M, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol. 2011;38:1480-1486.
Pillebout E, Alberti C, Guillevin L, Ouslimani A, Thervet E, The CESAR Study Group. Addition of cyclophosphamide to steroids provides no benefit compared with steroids alone in treating adult patients with severe Henoch Schönlein Purpura. Kidney Int. 2010;78:495-502.
Tobino K, Shimizu Y, Miura S, Sugawara K, Takeda K, Tomino Y. Severe erosive lesions in the digestive tract of patients with Henoch-Schönlein Purpura (HSP) and its impact on prognosis - presentation of two cases and statistical review of adult-onset Japanese HSP. Clin Nephrol. 2011;75(Suppl 1):47-55.
Demirkaya E, Ozen S, Pistorio A, et al. Performance of Birmingham Vasculitis Activity Score and disease extent index in childhood vasculitides. Clin Exp Rheumatol. 2012;30:162-168.
Augusto J-F, Sayegh J, Delapierre L, et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series. Am J Kidney Dis. 2012;59:663-669.
Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990;33:1114-1121.
Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med. 2000;19:311-315.
Sbarouni E, Georgiadou P, Voudris V. Ischemia modified albumin changes - review and clinical implications. Clin Chem Lab Med. 2011;49:177-184.
Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. Lab Invest. 1982;47:412-426.
Halliwell B, Chirico S. Lipid peroxidation: its mechanism, measurement, and significance. A J Clin Nutr. 1993;57:715-724.
Halliwell B, Gutteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys. 1990;280:1-8.
Garewal H. Antioxidants and Disease Prevention, Vol. 14. Boca Raton, FL: CRC Press.
Fridovich I. Superoxide dismutases. Annu Rev Biochem. 1975;1975(44):147-159.
Buyan N, Erbas D, Akkok N, Oz E, Biberoğlu G, Hasanoğlu E. Role of free oxygen radicals and prostanoids in the pathogenesis of Henoch-Schonlein Purpura. Prostaglandins Leukot Essent Fatty Acids. 1998;59:181-184.
Ece A, Kelekçi S, Kocamaz H, et al. Antioxidant enzyme activities, lipid peroxidation, and total antioxidant status in children with Henoch-Schönlein purpura. Clin Rheumatol. 2008;27:163-169.
Demircin G, Öner A, Ünver Y, Bülbül M, Erdoğan O. Erythrocyte superoxide dismutase activity and plasma malondialdehyde levels in children with Henoch-Schönlein purpura. Acta Pediatr. 1998;87:848-852.
Keskin N, Civilibal M, Elevli M, Koldas M, Duru NS, Ozturk H. Elevated plasma advanced oxidation protein products in children with Henoch-Schonlein purpura. Pediatr Nephrol. 2011;26:1989-1993.
Talwalkar SS, Bon Homme M, Miller JJ, Elin RJ. Ischemia modified albumin, a marker of acute ischemic events: a pilot study. Ann Clin Lab Sci. 2008;38:132-137.
Ozdemir M, Kivici A, Balevi A, Mevlitoğlu I, Peru C. Assessment of ischaemia- modified albumin level in patients with psoriasis. Clin Exp Dermatol. 2012;37:610-614.
Kadioğlu H, Ömür D, Bozkurt S, et al. Ischemia modified albumin can predict necrosis at incarcerated hernias. Dis Markers. 2013;35:807-810.
Valle Gottlieb MG, da Cruz I, Duarte M, et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab. 2010;95:586-591.
Dominguez-Rodriguez A, Abreu-Gonzalez P. Current role of ischemia- modified albumin in routine clinical practice. Biomarkers. 2010;15:655-662.
Klafke JZ, Porto FG, Batista R, et al. Association between hypertriglyceridemia and protein oxidation and proinflammatory markers in normocholesterolemic and hypercholesterolemic individuals. Clin Chim Acta. 2015;448:50-57.
Marx G, Chevinon M. Site specific modification of albumin by free radicals. Reaction with copper(II) and ascorbate. Biochem J. 1986;236:397-400.
Ali OS, Abdelgawad HM, Mohammed MS, El-Awady RR. Ischemic heart diseases in Egypt: role of xanthine oxidase system and ischemia-modified albumin. Heart Vessels. 2014;29:629-637.
Capkin E, Karkucak M, Kola M, Karaca A, Aydin Capkin A, Caner KS. Ischemia-modified albumin (IMA): a novel marker of vascular involvement in Behçet's disease? Joint Bone Spine. 2015;82:68-69.
Hattori Y, Nakanishi N, Kasai K, Murakami Y, Shimoda S. Tetrahydrobiopterin and GTP cyclohydrolase I in a rat model of endotoxic shock: relation to nitric oxide synthesis. Exp Physiol. 1996;81:665-671.
Hamerlinck FF. Neopterin: a review. Exp Dermatol. 1999;8:167-176.
Godal K, Uemasu J, Kawasaki H. Clinical significance of serum and urinary neopterins in patients with chronic renal disease. Clin Nephrol. 1991;36:141-146.
Moutabarrik A, Takahara S, Nakanishi I, et al. Interferon-g stimulates neopterin release from cultured kidney epithelial cells. Scand J Immunol. 1994;39:27-30.
Altindağ Z, Şahin G, Akpek G, et al. Urinary neopterin levels as an indicator of disease activation in Behçet's disease. Pteridines. 1995;6:79-83.
Altindag ZZ, Sahin G, Inanici F, Hascelik Z. Urinary neopterin excretion and dihydropteridine reductase activity in rheumatoid arthritis. Rheumatol Int. 1998;18:107-111.
Samsonov MY, Tilz GP, Egorova O, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus. 1995;4:29-32.
Nassonov E, Samsonov M, Beketova T, Semenkova L, Wachter H, Fuchs D. Serum neopterin concentrations in Wegener's granulomatosis correlate with vasculitis activity. Clin Exp Rheumatol. 1995;13:353-356.
Coskun B, Saral Y, Gödekmerdan A, Erden I, Coskun N. Activation markers in Behçet's disease. Skinmed. 2005;4:282-286.
Miray R, Ekinci K, Balci S, et al. MEFV gene variants in children with Henoch-Schönlein purpura and association with clinical manifestations: a single-center Mediterranean experience. Postgrad Med. 2019;131:68-72.
Altug U, Ensari C, Sayin DB, Ensari A. MEFV gene mutations in Henoch-Schönlein purpura. Int J Rheum Dis. 2013;16:347-351.